WFDC2 and benign neoplasm: A combination of HE4, CA125, carcinoembryonic antigen (CEA), and vascular cell adhesion molecule (VCAM)-1 in an assay panel has been tested for detecting early stage OVC versus benign tumors, and achieved 86 % sensitivity [41].